The mitochondrial DNA signal in rheumatoid arthritis: From metabolic victim to inflammatory driver¶

The finding¶

This 2026 review by Zhang et al. synthesizes evidence that mitochondrial DNA (mtDNA) is not merely collateral damage in rheumatoid arthritis (RA) but an active driver of innate immune signaling. The authors frame the field around a "mtDNA damage–release–immune activation axis": oxidative injury to mtDNA (due to limited chromatin protection and constrained repair) leads to its translocation to the cytosol or extracellular space, where it acts as an immunostimulatory danger signal. They also note that circulating cell-free mtDNA correlates with disease activity and therapeutic response, positioning it as a dynamic clinical biomarker.

Where it fits¶

This review speaks directly to the convergence point of Loop A and Loop B in the SAMHD1 p.A565T model — the mitochondrion as the organelle where the two chemically distinct DNA species diverge. The paper's central claim — that oxidized mtDNA is the immunostimulatory species — maps precisely onto the model's distinction: unoxidized mtDNA fragments exit via VDAC1 macropores to activate cGAS–STING (Loop A, IFN-I/JAK-STAT), while oxidized mtDNA (8-OHdG) primes NLRP3 (Loop B, mitochondrial/NLRP3). The review's emphasis on impaired mitochondrial quality control also resonates with the model's ISG15-mediated blockade of mitophagy via MFN1/2 and BECN1 — a mechanism that would keep damaged mitochondria leaking. For SAMHD1 A565T, where POLG replisome stress from dNTP pool expansion generates oxidized mtDNA, this framework reinforces the hypothesis that the same molecular species can feed two parallel inflammatory loops — and that targeting mtDNA release or sensing could be a dual-pronged therapeutic strategy.

Caveats¶

This is a review, not primary data — it synthesizes existing findings rather than presenting new mechanistic experiments.
The context is rheumatoid arthritis, not SAMHD1 A565T interferonopathy; the relevance to the model is analogical, not direct.
The review discusses mtDNA as a biomarker and driver in RA, but does not establish causal directionality in human disease, nor does it address heterozygous partial loss-of-function scenarios.

What to watch¶

The key translational question: does blocking oxidized mtDNA sensing (e.g., via NLRP3 inhibition) also suppress the cGAS-STING ISG signature in SAMHD1 A565T models — or are the loops sufficiently independent that dual blockade is required? The review's biomarker angle also raises a practical next step: whether circulating cell-free mtDNA could track disease activity in A565T carriers.

Source: The mitochondrial DNA signal in rheumatoid arthritis: From metabolic victim to inflammatory driver — 2026.